2022 - Research.com Immunology in Spain Leader Award
The scientist’s investigation covers issues in Internal medicine, Immunology, Antiphospholipid syndrome, Lupus erythematosus and Surgery. Many of his studies involve connections with topics such as Gastroenterology and Internal medicine. His Immunology research incorporates elements of Disease, Incidence and Family medicine.
His Antiphospholipid syndrome study focuses on Catastrophic antiphospholipid syndrome in particular. He has researched Lupus erythematosus in several fields, including Randomized controlled trial, Nephropathy, Systemic lupus erythematosus, Belimumab and Anti-SSA/Ro autoantibodies. The Surgery study combines topics in areas such as Cause of death and Obstetrics.
Ricard Cervera spends much of his time researching Internal medicine, Immunology, Antiphospholipid syndrome, Antibody and Thrombosis. His Internal medicine study combines topics in areas such as Gastroenterology and Surgery. Immunology connects with themes related to Disease in his study.
His study looks at the intersection of Antiphospholipid syndrome and topics like Lupus anticoagulant with Anticardiolipin antibodies. In Catastrophic antiphospholipid syndrome, he works on issues like Rituximab, which are connected to Refractory. His Lupus erythematosus study combines topics from a wide range of disciplines, such as Systemic lupus erythematosus and Anti-SSA/Ro autoantibodies.
His primary scientific interests are in Internal medicine, Antiphospholipid syndrome, Immunology, Intensive care medicine and Antibody. His studies link Gastroenterology with Internal medicine. Ricard Cervera is studying Catastrophic antiphospholipid syndrome, which is a component of Antiphospholipid syndrome.
His Immunology study deals with Disease intersecting with Genotype. His study in the field of Anticardiolipin antibodies is also linked to topics like In patient, International congress and Task force. As a part of the same scientific family, Ricard Cervera mostly works in the field of Lupus anticoagulant, focusing on Hydroxychloroquine and, on occasion, Systemic lupus erythematosus.
Internal medicine, Antiphospholipid syndrome, Immunology, Disease and Rheumatology are his primary areas of study. His Internal medicine study frequently draws parallels with other fields, such as Lupus erythematosus. His Antiphospholipid syndrome study results in a more complete grasp of Thrombosis.
His study on Rare disease is often connected to Clinical Practice as part of broader study in Disease. His Rheumatology study incorporates themes from Disease management, Incidence and Intensive care medicine. His studies in Gastroenterology integrate themes in fields like Lupus anticoagulant and Plasma samples.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
S. Miyakis;M. D. Lockshin;T. Atsumi;D. W. Branch.
Journal of Thrombosis and Haemostasis (2006)
Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients
Ricard Cervera;Jean Charles Piette;Josep Font;Munther A. Khamashta.
Arthritis & Rheumatism (2002)
Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients
Ricard Cervera;Munther A. Khamashta;Josep Font;Gian Domenico Sebastiani.
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie;Michelle Petri;Omid Zamani;Ricard Cervera.
Arthritis & Rheumatism (2011)
Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus
Cervera R;Khamashta Ma;Font J;Sebastiani Gd.
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
Frédéric A. Houssiau;Carlos Vasconcelos;David D'Cruz;Gian Domenico Sebastiani.
Arthritis & Rheumatism (2002)
Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Gerald B. Appel;Gabriel Contreras;Mary Anne Dooley;Ellen M. Ginzler.
Journal of The American Society of Nephrology (2009)
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
George K Bertsias;Maria Tektonidou;Zahir Amoura;Martin Aringer.
Annals of the Rheumatic Diseases (2012)
Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines
R A Asherson;R Cervera;P G de Groot;D Erkan.
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics
G. Bertsias;J. P. A. Ioannidis;J. Boletis;S. Bombardieri.
Annals of the Rheumatic Diseases (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: